[PDF][PDF] Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease
Journal of Clinical Oncology, 2007•academia.edu
Purpose Pediatric Oncology Group (POG) studies 9426 and 9425 evaluated dexrazoxane
(DRZ) as a cardiopulmonary protectant during treatment for Hodgkin's disease (HD). We
evaluated incidence and risk factors of acute myeloid leukemia (AML)/myelodysplastic
syndrome (MDS) and second malignant neoplasms (SMNs).
(DRZ) as a cardiopulmonary protectant during treatment for Hodgkin's disease (HD). We
evaluated incidence and risk factors of acute myeloid leukemia (AML)/myelodysplastic
syndrome (MDS) and second malignant neoplasms (SMNs).
Purpose
Pediatric Oncology Group (POG) studies 9426 and 9425 evaluated dexrazoxane (DRZ) as a cardiopulmonary protectant during treatment for Hodgkin’s disease (HD). We evaluated incidence and risk factors of acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) and second malignant neoplasms (SMNs).
academia.edu